In The News Posted April 19, 2019 Share Posted April 19, 2019 SILVER SPRING, Md., April 19, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription-only device, called the Monarch external Trigeminal Nerve Stimulation... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.